S-100和NSE作为黑色素瘤的血清标志物。

S-100 and NSE as serum markers in melanoma.

作者信息

Tofani A, Cioffi R P, Sciuto R, Rea S, Festa A, Di Filippo F, Cavaliere R, Maini C L

机构信息

Department of Nuclear Medicine, Regina Elena Cancer Institute, Rome.

出版信息

Acta Oncol. 1997;36(7):761-4. doi: 10.3109/02841869709001351.

DOI:10.3109/02841869709001351

PMID:9490097

Abstract

S-100 protein and neuron-specific enolase (NSE) have recently been proposed as serum markers for melanoma. In this study NSE and S-100 serum levels were assayed by commercial IRMA methods in 53 patients with melanoma. The overall prevalence of abnormal marker levels was similar for NSE (26%) and S-100 (30%). The 24 patients in stages I and II had uniformly normal S-100 levels, but abnormal NSE levels were observed in 3 out of the 12 patients in stage II (33%) and in 1 out of 12 in stage I. NSE appears thus to be the marker of choice in the early stages, where its increase points to disease progression. In patients in stages III and IV the prevalence of abnormal values was 34% for NSE and 55% for S-100 (p = < 0.05). In the latter group diagnostic sensitivity increased to 62% if isolated elevation of each marker was considered. In patients with advanced stage disease, both NSE and S-100 should be assayed.

摘要

S-100蛋白和神经元特异性烯醇化酶（NSE）最近被提议作为黑色素瘤的血清标志物。在本研究中，采用商业免疫放射分析方法对53例黑色素瘤患者的NSE和S-100血清水平进行了检测。NSE（26%）和S-100（30%）异常标志物水平的总体患病率相似。I期和II期的24例患者S-100水平均正常，但II期的12例患者中有3例（33%）和I期的12例患者中有1例NSE水平异常。因此，NSE似乎是早期阶段的首选标志物，其升高表明疾病进展。在III期和IV期患者中，NSE异常值的患病率为34%，S-100为55%（p = < 0.05）。在后一组中，如果考虑每个标志物的单独升高，诊断敏感性提高到62%。对于晚期疾病患者，应同时检测NSE和S-100。